Checkpoint Therapeutics, Inc

(NASDAQ:CKPT)

Latest On Checkpoint Therapeutics, Inc (CKPT):

Date/Time Type Description Signal Details
2023-05-24 00:53 ESTNewsCheckpoint Therapeutics prices $10M registered direct offeringN/A
2023-05-15 22:12 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.89N/A
2023-04-05 04:47 ESTNewsCheckpoint: Lesson On How To Destroy Shareholder Value With Serial, Small Financings Despite Good P3 Data And Pending PDUFA DateN/A
2023-03-31 18:38 ESTNewsCheckpoint Therapeutics GAAP EPS of -$7.09 misses by $2.36N/A
2023-03-31 18:38 ESTNewsCheckpoint Therapeutics to raise $6.1M in stock offeringN/A
2023-03-25 00:19 ESTNewsCheckpoint Therapeutics files for $150M mixed shelf offeringN/A
2023-03-02 14:40 ESTNewsCheckpoint's antibody therapy for skin cancer gets FDA reviewN/A
2023-02-21 09:19 ESTNewsCheckpoint Therapeutics stock dips on ~$7.5M securities offeringN/A
2023-01-10 21:00 ESTNewsCheckpoint Therapeutics: An Updated AnalysisN/A
2022-12-16 01:30 ESTNewsCheckpoint Therapeutics announces $7.5M direct offeringN/A
2022-12-05 23:33 ESTNewsCheckpoint Therapeutics falls 8.6% on 1-for-10 reverse stock splitN/A
2022-11-09 03:52 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.12 beats by $0.03, revenue of $0.05MN/A
2022-10-05 04:52 ESTNewsAstraZeneca – LogicBio deal indicates more such takeovers are ahead – CantorN/A
2022-09-08 09:07 ESTNewsCheckpoint: Strong Data, But Comes With RisksN/A
2022-08-12 16:52 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.16 in-line, revenue of $0.02M beats by $0.01MN/A
2022-06-16 16:45 ESTNewsCheckpoint Therapeutics trial generates positive interim results for skin cancer candidateN/A
2022-05-14 13:35 ESTNewsCheckpoint gains as H.C. Wainwright cheers key regulatory milestone in EuropeN/A
2022-05-13 08:45 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.20N/A
2022-04-19 04:11 ESTNewsCheckpoint Therapeutics: Potential Upside Based On Marketing Application SubmissionsN/A
2022-03-28 17:53 ESTNewsCheckpoint Therapeutics GAAP EPS of -$0.75 misses by $0.24, revenue of $0.27M misses by $0.09MN/A
2022-01-28 22:15 ESTNewsCheckpoint Therapeutics: Another Buying Opportunity Following Cosibelimab's Impressive Topline ResultsN/A
2022-01-26 03:24 ESTNewsCheckpoint Therapeutics jumps after trial win; Analysts boost price targetN/A
2022-01-25 10:34 ESTNewsCheckpoint reports positive results from registration trial of cosibelimab in skin cancerN/A
2021-11-26 14:13 ESTNewsCheckpoint Therapeutics: Pullback Provides Opportunity To Add Ahead Of Cosibelimab's Data ReadoutN/A
2021-10-02 08:21 ESTNewsCheckpoint Therapeutics (CKPT) Investor Presentation - SlideshowN/A
2021-08-06 00:08 ESTNewsCheckpoint Therapeutics EPS misses by $0.02, beats on revenueN/A
2021-07-21 00:45 ESTNewsBiogen’s risks fueling drug pricing debate Citi says, AstraZeneca remains top pick at BofA: in today's analyst actionN/A
2021-07-21 00:44 ESTNewsCheckpoint surges 24% on B. Riley buy initiation, 567% upside potentialN/A
2021-07-21 00:10 ESTNewsCheckpoint Therapeutics: Amassing A Position Ahead Of Cosibelimab DataN/A
2021-05-07 05:42 ESTNewsCheckpoint Therapeutics EPS beats by $0.01, misses on revenueN/A
2021-03-11 07:23 ESTFinancialsCompany financials have been released.Neutral
2021-03-11 03:22 ESTAnalyst RatingThe Analyst Target Price has decreased from $17.67 to $15.25.Neutral
2021-03-10 15:19 ESTEarnings EstimateAn EPS average of -$0.23 is estimated for the 2022 year.Sell
2021-03-10 15:19 ESTEarnings EstimateAn EPS average of -$0.08 is estimated for the quarter ending on June 30, 2021.Buy
2021-03-10 09:23 ESTNewsCheckpoint Therapeutics EPS misses by $0.09, misses on revenueN/A
2021-03-02 09:56 ESTNewsCheckpoint Therapeutics forms a scientific advisory boardN/A
2021-02-17 01:12 ESTNewsChecking In On Checkpoint TherapeuticsN/A
2021-01-20 15:54 ESTNewsCheckpoint Therapeutics initiated at Cantor with OverweightN/A
2021-01-20 11:23 ESTAnalyst RatingThe Analyst Target Price has decreased from $18.5 to $17.67.Neutral
2020-12-30 11:24 ESTAnalyst RatingThe Analyst Target Price has increased from $15 to $18.5.Buy
2020-12-18 09:17 ESTNewsCheckpoint Therapeutics launches $100M ATM equity offeringN/A
2020-12-13 03:33 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 23:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-07 15:24 ESTFinancialsCompany financials have been released.Neutral
2020-11-06 19:23 ESTEarnings EstimateAn EPS average of -$0.08 is estimated for the quarter ending on March 31, 2021.Buy
2020-11-06 07:22 ESTFinancialsCompany financials have been released.Neutral
2020-11-05 01:15 ESTNewsCheckpoint Therapeutics EPS misses by $0.01, misses on revenueN/A
2020-11-02 21:15 ESTNewsCheckpoint Therapeutics +10% after expanding cosibelimab manufacturing deal with Samsung BiologicsN/A
2020-11-01 17:32 ESTFinancialsCompany financials have been released.Neutral
2020-09-30 08:28 ESTAnalyst RatingThe Analyst Target Price has increased from $14.33 to $15.Buy

About Checkpoint Therapeutics, Inc (CKPT):

Checkpoint Therapeutics, Inc., an immuno-oncology biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers. The company's product candidates include CK-101 that in Phase I clinical trial for the treatment of epidermal growth factor receptor mutation-positive non-small cell lung cancer; and Cosibelimab, a programmed death ligand-1 (PD-L1), which is in Phase I clinical trial in patients with selected recurrent or metastatic cancers. It also develops CK-103, a small molecule inhibitor of BET bromodomains; and CK-302, a human agonistic antibody for oncology indications. Checkpoint Therapeutics, Inc. has collaboration agreements with TG Therapeutics, Inc. to develop and commercialize certain assets in connection with its licenses in the field of hematological malignancies. The company was founded in 2014 and is headquartered in New York, New York. Checkpoint Therapeutics, Inc. is a subsidiary of Fortress Biotech, Inc.

CKPT Quotes by TradingView

See Advanced Chart

General

  • Name Checkpoint Therapeutics, Inc
  • Symbol CKPT
  • Type Common Stock
  • Exchange NASDAQ
  • Currency USD
  • Country USA
  • SectorHealthcare
  • IndustryBiotechnology
  • Full Time Employees 10
  • Fiscal Year EndDecember
  • IPO Date2017-06-26
  • Gic SectorHealth Care
  • Gic GroupPharmaceuticals, Biotechnology & Life Sciences
  • Gic IndustryBiotechnology
  • Gic SubIndustryBiotechnology
  • Web URLhttp://www.checkpointtx.com
View More

Valuation

  • Price/Sales (Trailing 12 Mt.) 179.66
  • Price/Book (Most Recent Quarter) 7.31
  • Enterprise Value Revenue 203.89
View More

Financials

  • Most Recent Quarter 2020-12-31
  • Current Year EPS Estimate -$0.53
  • Next Year EPS Estimate -$0.62
  • Operating Margin -2170%
  • Return on Assets -42%
  • Return on Equity -85%
  • Revenue 1.07 million
  • Earnings Per Share -$1.01
  • Revenue Per Share $0.02
  • Gross Profit -15283000
  • Quarterly Earnings Growth 8%
View More

Highlights

  • Market Capitalization 249.71 million
  • PE Ratio -0.97
  • Analyst Target Price $15.25
  • Book Value Per Share $0.51
View More

Share Statistics

  • Shares Outstanding 68.21 million
  • Shares Float 59.96 million
  • % Held by Insiders 1262%
  • % Held by Institutions 21.39%
  • Shares Short 2.17 million
  • Shares Short Prior Month 2.37 million
  • Short Ratio 1.1
  • Short % of Float 4%
  • Short % of Shares Outstanding 3%
View More

Technicals

  • Beta 1.73
  • 52 Week High $5.38
  • 52 Week Low $1.05
  • 50 Day Moving Average 3.48
  • 200 Day Moving Average 2.9
View More

Dividends

  • Dividend Date N/A
  • ExDividend Date N/A
  • Dividend Yield 0%
View More

Checkpoint Therapeutics, Inc (CKPT) Dividend Calendar:

Ex-Dividend Date Payment Date Record Date Declared Date Amount

Checkpoint Therapeutics, Inc (CKPT) Earnings History:

Companies typically report earnings on both a quarterly and annual basis. Earnings reported that deviate from analysts' expectations can have a large impact on a stock's price.


Quarter Date Report Date Actual Revenue Reported EPS EPS Estimate Deviation from Estimate
2020-12-312021-03-09$27000-$0.17-$0.08-112.5%
2020-09-302020-11-04$N/A-$0.09-$0.08-12.5%
2020-06-302020-08-05$N/A-$0.09-$0.090%
2020-03-312020-05-06$N/A-$0.06-$0.1352.64%
2019-12-312020-03-11$25000-$0.22-$0.17-31.97%
2019-09-302019-11-07$280000-$0.15-$0.1710.02%
2019-06-302019-08-08$1.05 million-$0.15-$0.164.76%
2019-03-312019-05-09$352000-$0.18-$0.2733.33%
2018-12-312019-03-15$3.03 million-$0.38-$0.30-28.81%
2018-09-302018-11-02$5000-$0.32-$0.23-39.13%
2018-06-302018-08-07$127000-$0.23-$0.3432.35%
2018-03-312018-05-10$343000-$0.35-$0.20-75%
2017-12-312018-03-15$332000-$0.26-$0.3114.75%
2017-09-302017-11-03$349000-$0.26-$0.3321.21%
2017-06-302017-08-09$351000-$0.28-$0.26-7.69%
2017-03-312017-05-10$693000-$0.20-$0.2520%
2016-12-312017-03-17$498000-$0.34-$0.25-36.28%

Checkpoint Therapeutics, Inc (CKPT) Company Financial Statements:

Financial statements are reports prepared by a company's management to present their financial performance and position at a point in time. A general-purpose set of financial statements usually includes a balance sheet, income statements, and statement of cash flows.

Income Statement:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Research Development 8.15 million N/A N/A N/A 19.33 million
Income Before Tax -10.23 million N/A N/A N/A -8.83 million
Selling General Administrative 2.12 million N/A N/A N/A 2.15 million
Gross Profit N/A N/A N/A N/A 12.62 million
Ebit -10.24 million N/A N/A N/A -8.86 million
Operating Income -10.24 million N/A N/A N/A -8.86 million
Income Tax Expense N/A N/A N/A N/A N/A
Total Revenue 27000 N/A N/A N/A 25000
Cost of Revenue N/A N/A N/A N/A -12.6 million
Total Other Income Expense Net N/A N/A N/A N/A 31000
Net Income From Continuing Operations -10.23 million N/A N/A N/A -8.83 million
Net Income Applicable to Common Shares -10.23 million -4.93 million -4.65 million -3.28 million -8.83 million
Cash Flow:
Date Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019 Sep 30 2019
Investments N/A N/A N/A N/A N/A
Change to Liabilities N/A 723000 N/A N/A N/A
Total Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Net Borrowings N/A N/A N/A N/A N/A
Total Cash Flow from Financial Activities N/A N/A N/A N/A N/A
Change to Operating Activities N/A 34000 N/A N/A N/A
Change in Cash N/A N/A N/A N/A N/A
Total Cash from Operating Activities N/A -2.16 million N/A N/A N/A
Depreciation N/A N/A N/A N/A N/A
Other Cash Flow from Investing Activities N/A N/A N/A N/A N/A
Change to Inventory N/A N/A N/A N/A N/A
Change to Account Receivables N/A N/A N/A N/A N/A
Other Cash Flow from Financing Activities N/A -62000 N/A N/A N/A
Change to Net Income N/A 797000 N/A N/A N/A
Capital Expenditures N/A N/A N/A N/A N/A
Balance Sheet:
Date Dec 31 2020 Sep 30 2020 Jun 30 2020 Mar 31 2020 Dec 31 2019
Total Liabailities 7.22 million N/A N/A N/A 8.12 million
Total Stockholder Equity 35.38 million N/A N/A N/A 18.85 million
Other Current Liabilities N/A N/A N/A N/A N/A
Total Assets 42.6 million N/A N/A N/A 26.97 million
Common Stock 7000 7000 6000 6000 6000
Other Current Assets N/A N/A N/A N/A N/A
Retained Earnings -143.19 million -132.97 million -128.04 million -123.39 million -120.11 million
Other Liabilities N/A N/A N/A N/A N/A
Other Assets N/A N/A N/A N/A N/A
Cash 40.77 million N/A N/A N/A 26.08 million
Total Current Liabilities 7.22 million 6.42 million N/A N/A 8.12 million
Other Stockholder Equity 4.62 million N/A N/A 2.51 million 2.51 million
Property, Plant & Equipment N/A N/A N/A N/A N/A
Total Current Assets 42.6 million 42.65 million N/A N/A 26.97 million
Long Term Investments N/A N/A N/A N/A N/A
Net Tangible Assets 35.38 million 36.23 million 14.97 million 16.22 million 18.85 million
Short Term Investments N/A N/A N/A N/A N/A
Long Term Debt N/A N/A N/A N/A N/A
Inventory N/A N/A N/A N/A N/A
Accounts Payable 7.22 million 6.42 million N/A N/A 7.26 million

Checkpoint Therapeutics, Inc (CKPT) Chart:

Checkpoint Therapeutics, Inc (CKPT) News:

Below you will find a list of latest news for Checkpoint Therapeutics, Inc (CKPT) from major news sources. You can filter the results to only show news from a specific source.

No recent news available

Checkpoint Therapeutics, Inc (CKPT) Options:

A stock option is a contract between two parties in which the stock option buyer (holder) purchases the right (but not the obligation) to buy/sell 100 shares of an underlying stock at a predetermined price from/to the option seller (writer) within a fixed period of time.

Expiration Date Strike Last Price Type Volume Open Interest Implied Volatility In The Money Change Change Percent
2024-05-172.50.1CALL0 2690FALSE00
2024-05-1750CALL0 00FALSE00
2024-05-177.50CALL0 00FALSE00
2024-05-172.51.09PUT0 2162.2TRUE00
2024-05-1750PUT0 0639.37TRUE00
2024-05-177.50PUT0 0379.36TRUE00
2024-06-212.50CALL0 00FALSE00
2024-06-2150CALL0 00FALSE00
2024-06-217.50CALL0 00FALSE00
2024-06-212.51.1PUT0 0115.7TRUE00
2024-06-2150PUT0 0241.97TRUE00
2024-06-217.50PUT0 0254.03TRUE00
2024-07-192.50.15CALL0 2791140.34FALSE00
2024-07-1950.1CALL0 24540FALSE00
2024-07-197.50.3CALL0 800FALSE00
2024-07-192.51.2PUT0 1284301.27TRUE00
2024-07-1953.4PUT0 1487267.9TRUE00
2024-07-197.55.6PUT0 66247.25TRUE00
2024-10-182.50.28CALL0 293130.67FALSE00
2024-10-1850.2CALL0 430FALSE00
2024-10-187.50.2CALL0 200FALSE00
2024-10-182.51.45PUT0 87169.76TRUE00
2024-10-1853.4PUT0 119377.56TRUE00
2024-10-187.55.9PUT0 11185.53TRUE00

Latest CKPT Trades:

Date Shares Price
Jun 13, 2022 7:59 PM EST16$1.075
Jun 13, 2022 7:59 PM EST4$1.075
Jun 13, 2022 7:59 PM EST100$1.075
Jun 13, 2022 7:59 PM EST75$1.075
Jun 13, 2022 7:59 PM EST9$1.075

Checkpoint Therapeutics, Inc (CKPT) SEC Filings:

An SEC filing is a financial statement or other formal document submitted to the U.S. Securities and Exchange Commission (SEC). Public companies, certain insiders, and broker-dealers are required to make regular SEC filings.

Date Form Type Form Name Link
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071416/0001104659-20-071416-index.htm
2019-12-10SC 13G/AStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1651407/000083423719000377/0000834237-19-000377-index.htm
2019-11-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465919061166/0001104659-19-061166-index.htm
2019-11-1210-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000110465919061825/0001104659-19-061825-index.htm
2019-11-19424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1651407/000110465919065521/0001104659-19-065521-index.htm
2019-11-208-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465919065901/0001104659-19-065901-index.htm
2019-11-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1651407/000110465919066058/0001104659-19-066058-index.htm
2019-11-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465919066411/0001104659-19-066411-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920024924/0001104659-20-024924-index.htm
2020-02-254Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920024925/0001104659-20-024925-index.htm
2020-03-118-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920031949/0001104659-20-031949-index.htm
2020-03-1110-KAnnual report [Section 13 and 15(d), not S-K Item 405]https://www.sec.gov/Archives/edgar/data/1651407/000110465920032004/0001104659-20-032004-index.htm
2020-04-14PRE 14AOther preliminary proxy statementshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920046391/0001104659-20-046391-index.htm
2020-04-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920049043/0001104659-20-049043-index.htm
2020-04-24DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920050696/0001104659-20-050696-index.htm
2020-04-24DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1651407/000110465920050699/0001104659-20-050699-index.htm
2020-05-068-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920057496/0001104659-20-057496-index.htm
2020-05-0710-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920058103/0001104659-20-058103-index.htm
2020-05-22DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1651407/000110465920065134/0001104659-20-065134-index.htm
2020-05-224Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920065429/0001104659-20-065429-index.htm
2020-06-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920069838/0001104659-20-069838-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071407/0001104659-20-071407-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071409/0001104659-20-071409-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071411/0001104659-20-071411-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071412/0001104659-20-071412-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071414/0001104659-20-071414-index.htm
2020-06-094Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920071416/0001104659-20-071416-index.htm
2020-08-058-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920090877/0001104659-20-090877-index.htm
2020-08-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920091475/0001104659-20-091475-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920105877/0001104659-20-105877-index.htm
2020-09-178-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920106151/0001104659-20-106151-index.htm
2020-09-17424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920106159/0001104659-20-106159-index.htm
2020-09-18FWPFiling under Securities Act Rules 163/433 of free writing prospectuseshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920106177/0001104659-20-106177-index.htm
2020-09-21424B5Prospectus [Rule 424(b)(5)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920107034/0001104659-20-107034-index.htm
2020-09-218-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920107061/0001104659-20-107061-index.htm
2020-09-25SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1651407/000110465920108604/0001104659-20-108604-index.htm
2020-10-078-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920113132/0001104659-20-113132-index.htm
2020-11-048-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000110465920121374/0001104659-20-121374-index.htm
2020-11-0610-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000110465920122503/0001104659-20-122503-index.htm
2019-04-30DEF 14AOther definitive proxy statementshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419022087/0001144204-19-022087-index.htm
2019-04-30DEFA14AAdditional definitive proxy soliciting materials and Rule 14(a)(12) materialhttps://www.sec.gov/Archives/edgar/data/1651407/000114420419022091/0001144204-19-022091-index.htm
2019-05-018-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000114420419022661/0001144204-19-022661-index.htm
2019-05-098-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000114420419024954/0001144204-19-024954-index.htm
2019-05-1010-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000114420419025063/0001144204-19-025063-index.htm
2019-06-128-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000114420419030716/0001144204-19-030716-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031016/0001144204-19-031016-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031017/0001144204-19-031017-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031018/0001144204-19-031018-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031021/0001144204-19-031021-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031022/0001144204-19-031022-index.htm
2019-06-144Statement of changes in beneficial ownership of securitieshttps://www.sec.gov/Archives/edgar/data/1651407/000114420419031023/0001144204-19-031023-index.htm
2019-08-088-KCurrent reporthttps://www.sec.gov/Archives/edgar/data/1651407/000114420419038589/0001144204-19-038589-index.htm
2019-08-0810-QQuarterly report [Sections 13 or 15(d)]https://www.sec.gov/Archives/edgar/data/1651407/000114420419038614/0001144204-19-038614-index.htm
2020-09-18SC 13GStatement of acquisition of beneficial ownership by individualshttps://www.sec.gov/Archives/edgar/data/1651407/000153561020000112/0001535610-20-000112-index.htm

Checkpoint Therapeutics, Inc (CKPT) Insider Transactions:

Here you will find a list of insider trading activities (stock purchases, sales, and option exercises) reported by insiders of Checkpoint Therapeutics, Inc (CKPT). Company insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise.
Insider Ownership: 1262%
Institutional Ownership: 2139%

Transaction Date Insider Name Insider Title Type Shares Number Shares Price Total Transaction Shares Held After Transaction Link
2019-06-13Scott BoilenDirectorBuy11,442.00110,112.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031017/0001144204-19-031017-index.htm
2020-06-05BARRY M SALZMANDirectorBuy24,390.00112,280.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071412/0001104659-20-071412-index.htm
2020-06-05Neil HerskowitzDirectorBuy24,390.00112,280.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071411/0001104659-20-071411-index.htm
2020-06-05Scott BoilenDirectorBuy24,390.00134,502.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071409/0001104659-20-071409-index.htm
2019-06-13LINDSAY A MD ROSENWALDDirectorBuy11,442.00137,890.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031021/0001144204-19-031021-index.htm
2019-11-20LINDSAY A MD ROSENWALDDirectorBuy100,000.001.27127,000.00237,890.00https://www.sec.gov/Archives/edgar/data/1651407/000110465919066411/0001104659-19-066411-index.htm
2020-06-05LINDSAY A MD ROSENWALDDirectorBuy24,390.00262,280.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071416/0001104659-20-071416-index.htm
2020-02-24James F III OlivieroCEO, President and DirectorBuy598,000.002,733,000.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920024924/0001104659-20-024924-index.htm
2020-05-21WILLIAM GARRETT GRAYOfficerSell17,104.002.0034,122.48359,896.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920065429/0001104659-20-065429-index.htm
2020-02-24WILLIAM GARRETT GRAYOfficerBuy157,000.00377,000.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920024925/0001104659-20-024925-index.htm
2019-06-13MICHAEL S WEISSDirectorBuy11,442.0037,890.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031023/0001144204-19-031023-index.htm
2019-06-13Christian BechonDirectorBuy11,442.0061,442.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031016/0001144204-19-031016-index.htm
2020-06-05MICHAEL S WEISSDirectorBuy24,390.0062,280.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071414/0001104659-20-071414-index.htm
2020-06-05Christian BechonDirectorBuy24,390.0085,832.00https://www.sec.gov/Archives/edgar/data/1651407/000110465920071407/0001104659-20-071407-index.htm
2019-06-13BARRY M SALZMANDirectorBuy11,442.0087,890.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031022/0001144204-19-031022-index.htm
2019-06-13Neil HerskowitzDirectorBuy11,442.0087,890.00https://www.sec.gov/Archives/edgar/data/1651407/000114420419031018/0001144204-19-031018-index.htm